Publications by authors named "MCarmen Carmona-Garcia"
Objectives: To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19.
Methods: The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patients who received systemic anti-cancer therapy in the 4 weeks before laboratory-confirmed COVID-19 diagnosis. Propensity-score matching using country, vaccination status, primary tumor type, sex, age, comorbidity burden, tumor stage, and remission status investigated differences in predefined clinical outcomes comparing those who had or had not received ICIs.
Article Synopsis
- A study found that many cancer patients who recover from COVID-19 experience lasting effects, known as post-COVID-19 sequelae, which can impact their ongoing cancer care and outcomes.
- Among 186 patients studied, 16.6% reported persistent symptoms like fatigue and respiratory issues within a few months of recovering from COVID-19, with some symptoms lasting up to 12 months.
- The results emphasize the importance of monitoring and supporting cancer patients after COVID-19, especially since many in the study were unvaccinated and had previously complicated cases of the virus.
Background: Fifteen percent of patients with cancer experience symptomatic sequelae, which impair post-COVID-19 outcomes. In this study, we investigated whether a proinflammatory status is associated with the development of COVID-19 sequelae.
Methods: OnCovid recruited 2795 consecutive patients who were diagnosed with Severe Acute Respiratory Syndrome Coronavirus 2 infection between February 27, 2020, and February 14, 2021.